Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,

Slides:

Advertisements

Similar presentations

A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.

Advertisements

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Treatment of early-stage Hodgkin lymphoma

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study by Martin Schrappe, Maria.

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

Alternate designs for conduct and analysis of phase I cancer trials

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study by Jasmijn D. E. de Rooij, Riccardo.

How I treat elderly patients with myeloma

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations by Mark J. Levis, Alexander E.

Nonmyeloablative conditioning for relapsed follicular lymphoma

Short-pulse B–non-Hodgkin lymphoma–type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster.

A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid.

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Imatinib for refractory chronic graft-versus-host disease with fibrotic features by Attilio Olivieri, Franco Locatelli, Marco Zecca, Adele Sanna, Michele.

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? by Marc Michel, Nichola Cooper, Christelle Jean, Christine Frissora, and.

Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study by Andreas K. Øvlisen, Anders Oest,

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232 by Michael J. Borowitz,

Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia by Sarah Bertoli,

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies by Brigitte T. A. van den Broek, Kristin.

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

by Geling Li, Emily Waite, and Julie Wolfson

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission by Sumithira Vasu, Jessica.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia by Thai Hoa Tran, Marian.

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia by Lili Aslostovar, Allison L. Boyd, Mohammed.

by Mieke Aldenhoven, Brigitte T. A. van den Broek, Robert F

by Christine L. Kempton, and Amanda B. Payne

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,

by Giovanni Palladini, and Giampaolo Merlini

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.

Positron emission tomography–computed tomography predictors of progression after DA-R-EPOCH for PMBCL by Chelsea C. Pinnix, Andrea K. Ng, Bouthaina S.

by Wendy Lim, Sara K. Vesely, and James N. George

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia by Andrew Wei, Stephen.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.

A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF ) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic.

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia by Ondrej Hrusak, Valerie de Haas, Jitka Stancikova,

How I treat refractory and early relapsed acute myeloid leukemia

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance by Alexandra M. Stevens, Jennifer.

How I treat T-cell acute lymphoblastic leukemia in adults

Balancing bleeding in brain metastases

Cold agglutinin disease

Outcomes in patients with PTCL

Presentation transcript:

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann, Ursula Creutzig, Katarina Reinhardt, Femke Verwer, Valerie de Haas, Vincent H. J. van der Velden, Christine von Neuhoff, C. Michel Zwaan, Dirk Reinhardt, and Jan-Henning Klusmann BloodAdv Volume 2(13):1532-1540 July 10, 2018 © 2018 by The American Society of Hematology

Marius Flasinski et al. Blood Adv 2018;2:1532-1540 © 2018 by The American Society of Hematology

Overview of the TMD Prevention 2007 study. Overview of the TMD Prevention 2007 study. (A) Treatment plan of the TMD07 study. (B) Flowchart of patients enrolled in the TMD07 study. Marius Flasinski et al. Blood Adv 2018;2:1532-1540 © 2018 by The American Society of Hematology

Outcome of TMD07 patients compared with the historical control. Outcome of TMD07 patients compared with the historical control. (A) OS. (B) EFS. (C) CI of early death. Five-year probabilities are given in panels A and B. Marius Flasinski et al. Blood Adv 2018;2:1532-1540 © 2018 by The American Society of Hematology

Outcome of symptomatic TMD07 patients (intention-to-treat at diagnosis) compared with symptomatic patients in the historical control. Outcome of symptomatic TMD07 patients (intention-to-treat at diagnosis) compared with symptomatic patients in the historical control. (A) OS. (B) EFS. (C) CI of early death. Five-year probabilities are given in panels A and B. Marius Flasinski et al. Blood Adv 2018;2:1532-1540 © 2018 by The American Society of Hematology

Progression to ML-DS. Progression to ML-DS. CI of ML-DS: (A) TMD07 patients compared with the historical control. (B) Per protocol analysis: Treated TMD07 patients compared with asymptomatic, MRD-negative, untreated TMD07 patients and to the historical control. (C) MRD-positive TMD07 patients compared with MRD-negative TMD07 patients in week 12. Five-year probabilities are given in panels A through C. Marius Flasinski et al. Blood Adv 2018;2:1532-1540 © 2018 by The American Society of Hematology